Emyria Ltd (OTC:EMYRF) Filings

Emyria Ltd

Filings

FilingDateTypeFiled with
Emyria Recruits 31 Therapists to Meet Growing Patient DemandNov 18, 2026Operations updateASX
Change of Director's Interest Notice x 2Nov 17, 2026Ownership change noticeASX
Application for quotation of securities - EMDNov 17, 2026FinancingASX
Final Director's Interest Notice - J. TookeNov 12, 2026Ownership change noticeASX
Results of Annual General MeetingNov 12, 2026Meeting outcomeASX
2026 Annual General Meeting PresentationNov 11, 2026Annual reportASX
Notification of cessation of securities - EMDNov 10, 2026FinancingASX
September 2026 Quarterly Investor Webinar PresentationNov 1, 2026Quarterly reportASX
September 2026 Quarterly Investor Update Webinar InvitationOct 29, 2026Meeting noticeASX
September 2026 Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
September 2026 Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
Annual ReportOct 8, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementOct 8, 2026Other filingsASX
Letter to Shareholders - Notice of Annual General MeetingOct 8, 2026Meeting noticeASX
Notice of Annual General Meeting/Proxy FormOct 8, 2026Meeting noticeASX
Retirement of Non-Executive DirectorOct 8, 2026Management or board changeASX
Webinar with Former Secretary of Veterans Affairs Dr ShulkinOct 5, 2026Other filingsASX
Notification of cessation of securities - EMDOct 5, 2026FinancingASX
Emyria Successfully Opens First NSW Empax ClinicSep 28, 2026Other filingsASX
Application for quotation of securities - EMDSep 24, 2026FinancingASX
Former US Veterans Affairs Secretary Joins EmyriaSep 20, 2026Management or board changeASX
Emyria Presentation at FDA HearingSep 15, 2026Operations updateASX
FDA Selects EMD to Present at Psychedelic Medicines HearingSep 9, 2026Operations updateASX
Emyria Set to Launch First NSW ClinicSep 7, 2026Other filingsASX
Emyria Year End Presentation for Investor WebinarSep 7, 2026Other filingsASX
Emyria Financial Year-end Update WebinarSep 6, 2026Other filingsASX
Revised Securities Trading PolicySep 6, 2026Other filingsASX
Appendix 4E & Annual Financial Report Year End 30 June 2026Aug 31, 2026Annual reportASX
2026 Annual General Meeting - Key DatesAug 31, 2026Meeting noticeASX
Emyria Unlocks Treatment CapacityAug 19, 2026Operations updateASX
Notification of cessation of securities - EMDAug 16, 2026FinancingASX
Change of Registered Office and Principal Place of BusinessAug 9, 2026Other filingsASX
June 2026 Quarterly Activities Report and Appendix 4CJul 28, 2026Quarterly reportASX
June 2026 Quarterly Investor WebinarJul 28, 2026Meeting noticeASX
Emyria Depression Program Shows Positive ResultsJun 23, 2026ResultsASX
Emyria Confirms NSW Workforce Ahead of Clinic OpeningJun 21, 2026Other filingsASX
Emyria Company Update PresentationJun 10, 2026Operations updateASX
TGA Update to Accelerate Empax Therapist RecruitmentMay 27, 2026Operations updateASX
Emyria Activates First Victorian Empax ClinicMay 17, 2026Operations updateASX
March Quarter Investor Video PresentationMay 4, 2026Quarterly reportASX
Emyria Extends National Expansion into New South WalesApr 28, 2026Operations updateASX
March 2026 Quarterly Activities Report and Appendix 4CApr 27, 2026Quarterly reportASX
Emyria Launches Global Partnership ProgramApr 19, 2026Operations updateASX
EMD Commences NSW Workforce Recruitment To Support ExpansionApr 1, 2026Operations updateASX
Key Milestones Achieved for First Victorian Empax ClinicMar 23, 2026Operations updateASX
Appendix 4D and Half Year End Financial ReportFeb 26, 2026Interim reportASX
Medibank Expands Funding to Emyria's Victorian ClinicFeb 15, 2026Operations updateASX
Emyria's PTSD Program Delivers Lasting RecoveryFeb 1, 2026ResultsASX
December 2025 Quarterly Activities Report and Appendix 4CJan 27, 2026Quarterly reportASX
Victorian Clinic Confirmed, National Rollout ProceedingDec 15, 2025Operations updateASX
Emyria's Perth Expansion a Template for East Coast RolloutDec 10, 2025Operations updateASX
Institutional Placement Accelerates EMD National ExpansionNov 19, 2025FinancingASX
Trading HaltNov 17, 2025Trading halt or suspensionASX
September 2025 Quarterly Activities Report and Appendix 4COct 26, 2025Quarterly reportASX
Medibank Expands Funding Agreement to Emyria Brisbane ClinicOct 14, 2025Operations updateASX
Emyria Secures Medibank Funding for Depression Care ProgramSep 22, 2025Operations updateASX
Appendix 4E & Annual Report for the Year Ended 30 June 2025Aug 27, 2025Annual reportASX
Emyria to Expand Perth Clinic to Meet Growing DemandAug 26, 2025Other filingsASX
Emyria Commences National Expansion with Avive in BrisbaneJul 28, 2025Operations updateASX
June 2025 Quarterly Activities Report and Appendix 4CJul 28, 2025Quarterly reportASX
Medibank to Fund Emyria's PTSD Program at Perth ClinicJun 18, 2025Operations updateASX
PTSD Gains Sustained at 6m Follow-Up, MOU Signed with ANUMay 27, 2025ResultsASX
March 2025 Quarterly Activities Report and Appendix 4CApr 28, 2025Quarterly reportASX
Emyria Opens New Empax Centre to Meet Demand and Payer NeedsApr 13, 2025Operations updateASX
Emyria Reports Promising 3-Month PTSD Treatment ResultsFeb 3, 2025ResultsASX
December 2024 Quarterly Activities Report and Appendix 4CJan 31, 2025Quarterly reportASX
Leadership UpdatesJan 21, 2025Management or board changeASX
Emyria Secures $2.525M in Strongly Supported PlacementNov 26, 2024FinancingASX
Response to ASX Price QueryNov 12, 2024Explanation requestASX
Emyria & UWA Partner to License Novel Serotonin TherapiesOct 30, 2024Operations updateASX
September 2024 Quarterly Activities Report and Appendix 4COct 29, 2024Quarterly reportASX
Emyria Gains Ethics Endorsement for Psilocybin ProgramOct 27, 2024Operations updateASX
Emyria Shares Interim Success in PTSD Treatment ProgramSep 2, 2024ResultsASX
Appendix 4E & Annual Report for the Year Ended 30 June 2024Aug 30, 2024Annual reportASX
June 2024 Quarterly Activities Report and Appendix 4CJul 29, 2024Quarterly reportASX
Emyria, UWA Secure $499K Grant for MDMA Analogue ProgramJun 30, 2024Other filingsASX
Empax Centre Selected As Key Site In Global PTSD StudyJun 19, 2024Operations updateASX
March 2024 Quarterly Activities Report and Appendix 4CApr 25, 2024Quarterly reportASX
Emyria Receives Bids of $2.3M to Expand Clinical ServicesApr 23, 2024FinancingASX
Emyria Opens Empax Centre to Advance Mental Health CareApr 9, 2024Operations updateASX
Emyria Expands Specialist AP Team - First Female for MDMA-ATApr 4, 2024Operations updateASX
Emyria, Reach Wellness Enter MDMA-AT Research AgreementApr 2, 2024Operations updateASX
Response to ASX Aware QueryMar 12, 2024Explanation requestASX
December 2023 Quarterly Activities Report and Appendix 4CJan 30, 2024Quarterly reportASX
Emyria Receives $2.5M R&D Tax Incentive RefundJan 14, 2024ResultsASX
Emyria Specialist Granted Authorised Prescriber StatusJan 9, 2024Operations updateASX
Board Changes and Executive RestructuringNov 12, 2023Management or board changeASX
Emyria Secures Ethics Endorsement for MDMA AP ApplicationOct 29, 2023Operations updateASX
September 2023 Quarterly Activities Report and Appendix 4COct 25, 2023Quarterly reportASX
Health Canada Approval Received for MDMA ImportOct 18, 2023Operations updateASX
Emyria's Clinic Achieves Key MDMA-AT Dosing MilestoneOct 8, 2023Operations updateASX
Completion of Entitlement OfferOct 5, 2023FinancingASX
Emyria Secures Local MDMA to Start PTSD Trial DosingSep 20, 2023Other filingsASX
Emyria Completes Acquisition of the Pax CentreSep 13, 2023Acquisition or disposalASX
Strategic Update & Entitlement Offer PresentationSep 5, 2023FinancingASX
ProspectusSep 5, 2023Offer documentASX
Emyria Gets $2M Bids, Sets $3.1M Entitlement OfferSep 4, 2023FinancingASX
Appendix 4E Preliminary Financial ReportAug 30, 2023ResultsASX
Emyria Launches Ketamine-Assisted Therapy ProgramAug 7, 2023Other filingsASX
June 2023 Quarterly Activities Report and Appendix 4CJul 31, 2023Quarterly reportASX
Emyria Recruits First Patient MDMA-Assisted Therapy TrialJul 9, 2023Other filingsASX
Presentation - Pax Acquisition and Company UpdateJul 5, 2023Acquisition or disposalASX
Pax Centre Acquisition to Advance Psychedelic TherapiesJul 3, 2023Acquisition or disposalASX
Emyria Receives Ethics Approval for MDMA-assisted TherapyJun 7, 2023Other filingsASX
Emyria Completes $2.5m PlacementMay 1, 2023FinancingASX
March 2023 Quarterly Activities Report and Appendix 4CApr 28, 2023Quarterly reportASX
Emyria Unveils Highest Potency CBD Capsule for FDA PathwayApr 23, 2023Other filingsASX
Emyria to Develop Psilocybin Therapy Care ModelApr 17, 2023Other filingsASX
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5Apr 3, 2023Other filingsASX
Strong Recruitment for EMD-RX5 Phase 3 TrialMar 22, 2023Other filingsASX
Emyria Grows MDMA Asset for Neuro & Mental Health TherapyMar 19, 2023Other filingsASX
Emyria partners with PAX Centre for MDMA-assisted therapyMar 6, 2023Other filingsASX
Half Yearly Report and AccountsFeb 26, 2023Interim reportASX
Emyria secures clinical-grade MDMA supply for Aust patientsFeb 12, 2023Other filingsASX
Emyria expands MDMA programs following landmark TGA decisionFeb 5, 2023Other filingsASX
Appendix 4C - QuarterlyJan 30, 2023Quarterly reportASX
First dosing commenced for pivotal EMD-RX5 Phase 3 trialJan 29, 2023Other filingsASX
Emyria receives $2.1M R&D tax incentive refundJan 11, 2023Other filingsASX
Emyria accepted into National Institutes of Health ProgramNov 27, 2022Other filingsASX
Placement completion and secondary trading noticeNov 22, 2022FinancingASX
Emyria completes $3m placementOct 30, 2022FinancingASX
Emyria and UWA expand unique MDMA-inspired analogue libraryOct 17, 2022Other filingsASX
Emyria expands clinical sites for EMD-RX5 Phase 3 trialSep 25, 2022Other filingsASX
Emyria commences US preclinical program for MDMA librarySep 19, 2022Other filingsASX
Appendix 4E and Annual ReportAug 29, 2022Annual reportASX
Positive results received for Emyrias MDMA-inspired programAug 17, 2022Other filingsASX
Emyria receives ethics approval for EMD-RX5 Phase 3 trialAug 16, 2022Other filingsASX
Preclinical studies initiated for MDMA-inspired analoguesAug 4, 2022Other filingsASX
Emyria expands drug candidate library inspired by MDMAJul 17, 2022Other filingsASX
Emyria expands MDMA analogue program with UWAMay 31, 2022Other filingsASX
EMD-RX5 demonstrates excellent safety and bioavailabilityMay 24, 2022Other filingsASX
Further positive MDMA analogue screening results receivedMay 9, 2022Other filingsASX
Emyria launches second ultra-pure CBD capsuleMar 16, 2022Other filingsASX
Recruitment commenced for EMD-RX5 Phase 1 StudyMar 8, 2022Other filingsASX
Ethics approval received for EMD-RX5 Phase 1 StudyMar 3, 2022Other filingsASX
Emyria grows its novel MDMA-analogue libraryFeb 21, 2022Other filingsASX
Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBDJan 19, 2022Other filingsASX
Emyria adds wearables to psychedelic-assisted therapy trialsDec 19, 2021Other filingsASX
Pause in TradingDec 15, 2021Trading halt or suspensionASX
Positive animal data for Emyrias ultra-pure CBD capsuleDec 14, 2021Other filingsASX
Positive initial MDMA-analogue screening resultsDec 7, 2021Other filingsASX
Emyria receives $1,162,000 R&D Tax Incentive RefundNov 23, 2021Other filingsASX
Emyria Welcomes Tattarang as Strategic InvestorNov 21, 2021Other filingsASX
MDMA Analogue Development MilestoneOct 18, 2021Other filingsASX
Emyria selected to join Palantirs Foundry Builders ProgramOct 6, 2021Other filingsASX
Novel MDMA Analogue Screening Program AdvancedSep 21, 2021Other filingsASX
Emyria Expands Psychiatry Advisory for Psychedelics and MDMASep 15, 2021Other filingsASX
MDMA-analogues Show Promise for Parkinsons DiseaseAug 31, 2021Other filingsASX
Emyria Engages Calvert Labs for Preclinical CBD studiesAug 26, 2021Other filingsASX
Emyria Appoints Expert Neuropharmacologist for MDMA ProgramAug 19, 2021Other filingsASX
Emyria Executes Pure CBD Agreement with AltaSciencesAug 12, 2021Other filingsASX
Emyria to Develop Novel Psychedelics Pipeline with UWAAug 4, 2021Other filingsASX
Emyria Advances EMD-004 Program Towards RegistrationJun 14, 2021Other filingsASX
Emyria Data Validated, Care Model Reduces OpioidsJun 6, 2021Other filingsASX
Emyria Obtains TGA Approval for Medical Grade Monitoring AppMay 12, 2021Other filingsASX
Emyria and MMA launch MDMA-assisted therapy program for PTSDMay 4, 2021Other filingsASX
$5m Placement for Drug Registration and Treatment PipelineApr 21, 2021FinancingASX
Emyria and Cann Partner to Register CBD ProductMar 28, 2021Other filingsASX
Emyria Adds Second Clinical Site in PerthMar 1, 2021Other filingsASX
Emyria adds second Emerald Clinic in MelbourneFeb 9, 2021Other filingsASX
Emyria wins digital health monitoring grant with UWAFeb 4, 2021Other filingsASX
FDA Position on RWE to Guide RegistrationJan 26, 2021Other filingsASX
Emyria Pursuing Registration of EMD-003 in CY2021Jan 4, 2021Other filingsASX
Emyria to Benefit from Final TGA Ruling on CBD MedicinesDec 15, 2020Other filingsASX
Emyria Sees Strong Interest in IBS StudyDec 3, 2020Other filingsASX
Emyria Launches Drug Development Program Based on RWENov 24, 2020Other filingsASX
Emyria Partners with Thought Leaders in Psychedelic TherapyNov 18, 2020Other filingsASX
Emyria Enters Data Deal with ZLD to Support Autism TrialNov 8, 2020Other filingsASX
Webinar on Global Partnership with Sapphire Medical ClinicsOct 21, 2020Other filingsASX
Emyria Signs Real-World Data Agreement with ZeliraSep 29, 2020Other filingsASX
Preliminary Final Report and Full Year Statutory AccountsAug 31, 2020Annual reportASX
Emerald Clinics Successfully Raises $2.2m in PlacementAug 28, 2020FinancingASX
Record Appointments International Expansion and Name ChangeAug 13, 2020Other filingsASX
Emerald Signs RWE Contract with Canopy Growth UK CompanyAug 9, 2020Other filingsASX
EMDs Digital Health Platform Expands with New TechnologyJun 21, 2020Other filingsASX
EMD Program Manager of National Clinical Data and AnalyticsMay 11, 2020Other filingsASX